Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2013

Open Access 01-02-2013 | Research article

Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus

Authors: Ornella J Rullo, Jennifer MP Woo, Miriam F Parsa, Alice DC Hoftman, Paul Maranian, David A Elashoff, Timothy B Niewold, Jennifer M Grossman, Bevra H Hahn, Maureen McMahon, Deborah K McCurdy, Betty P Tsao

Published in: Arthritis Research & Therapy | Issue 1/2013

Login to get access

Abstract

Introduction

Osteopontin (OPN) has been implicated as a mediator of Th17 regulation via type I interferon (IFN) receptor signaling and in macrophage activity at sites of tissue repair. This study assessed whether increased circulating plasma OPN (cOPN) precedes development of organ damage in pediatric systemic lupus erythematosus (pSLE) and compared it to circulating plasma neutrophil gelatinase-associated lipocalin (cNGAL), a predictor of increased SLE disease activity.

Methods

cOPN and cNGAL were measured in prospectively followed pSLE (n = 42) and adult SLE (aSLE; n = 23) patients and age-matched controls. Time-adjusted cumulative disease activity and disease damage were respectively assessed using adjusted-mean SLE disease activity index (SLEDAI) (AMS) and SLICC/ACR damage index (SDI).

Results

Compared to controls, elevated cOPN and cNGAL were observed in pSLE and aSLE. cNGAL preceded worsening SLEDAI by 3-6 months (P = 0.04), but was not associated with increased 6-month AMS. High baseline cOPN, which was associated with high IFNalpha activity and expression of autoantibodies to nucleic acids, positively correlated with 6-month AMS (r = 0.51 and 0.52, P = 0.001 and 0.01 in pSLE and aSLE, respectively) and was associated with SDI increase at 12 months in pSLE (P = 0.001). Risk factors for change in SDI in pSLE were cOPN (OR 7.5, 95% CI [2.9-20], P = 0.03), but not cNGAL, cumulative prednisone, disease duration, immunosuppression use, gender or ancestry using univariate and multivariate logistic regression. The area under the curve (AUC) when generating the receiver-operating characteristic (ROC) of baseline cOPN sensitivity and specificity for the indication of SLE patients with an increase of SDI over a 12 month period is 0.543 (95% CI 0.347-0.738; positive predictive value 95% and negative predictive value 38%).

Conclusion

High circulating OPN levels preceded increased cumulative disease activity and organ damage in SLE patients, especially in pSLE, and its value as a predictor of poor outcome should be further validated in large longitudinal cohorts.
Appendix
Available only for authorised users
Literature
1.
Alarcon GS: Lessons from LUMINA: a multiethnic US cohort. Lupus. 2008, 17: 971-976. 10.1177/0961203308094359.CrossRefPubMed
2.
Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G: High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002, 29: 1398-1400.PubMed
3.
Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS: Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001, 10: 93-96. 10.1191/096120301670679959.CrossRefPubMed
4.
Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008, 58: 556-562. 10.1002/art.23204.CrossRefPubMed
5.
Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS: Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008, 17: 314-322. 10.1177/0961203307087875.PubMedCentralCrossRefPubMed
6.
Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM: Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002, 46: 436-444. 10.1002/art.10072.CrossRefPubMed
7.
Suzuki M, Wiers KM, Klein-Gitelman MS, Haines KA, Olson J, Onel KB, O'Neil K, Passo MH, Singer NG, Tucker L, Ying J, Devarajan P, Brunner HI: Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol. 2008, 23: 403-412. 10.1007/s00467-007-0685-x.CrossRefPubMed
8.
Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, Haines KA, Onel K, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI: Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009, 60: 2772-2781. 10.1002/art.24751.PubMedCentralCrossRefPubMed
9.
Suzuki M, Wiers K, Brooks EB, Greis KD, Haines K, Klein-Gitelman MS, Olson J, Onel K, O'Neil KM, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI: Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res. 2009, 65: 530-536. 10.1203/PDR.0b013e31819e4305.PubMedCentralCrossRefPubMed
10.
Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol. 2005, 16: 467-473. 10.1681/ASN.2004080658.CrossRefPubMed
11.
Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C: Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009, 11: R143-10.1186/ar2816.PubMedCentralCrossRefPubMed
12.
Tian S, Li J, Wang L, Liu T, Liu H, Cheng G, Liu D, Deng Y, Gou R, Wan Y, Jia J, Chen C: Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res. 2007, 56: 304-310. 10.1007/s00011-007-6147-x.CrossRefPubMed
13.
Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH: Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 2008, 74: 799-807. 10.1038/ki.2008.316.PubMedCentralCrossRefPubMed
14.
Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB: Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 2009, 10: 487-494. 10.1038/gene.2009.15.PubMedCentralCrossRefPubMed
15.
Trivedi T, Franek BS, Green SL, Kariuki SN, Kumabe M, Mikolaitis RA, Jolly M, Utset TO, Niewold TB: Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus. J Biomed Biotechnol. 2011, 2011: 802581-PubMedCentralCrossRefPubMed
16.
Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, Cantor H: Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol. 2006, 7: 498-506. 10.1038/ni1327.PubMedCentralCrossRefPubMed
17.
Shinohara ML, Kim JH, Garcia VA, Cantor H: Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity. 2008, 29: 68-78. 10.1016/j.immuni.2008.05.008.PubMedCentralCrossRefPubMed
18.
Patarca R, Wei FY, Singh P, Morasso MI, Cantor H: Dysregulated expression of the T cell cytokine Eta-1 in CD4-8- lymphocytes during the development of murine autoimmune disease. J Exp Med. 1990, 172: 1177-1183. 10.1084/jem.172.4.1177.CrossRefPubMed
19.
Wong CK, Lit LC, Tam LS, Li EK, Lam CW: Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005, 44: 602-606. 10.1093/rheumatology/keh558.CrossRef
20.
Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R: Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol. 1996, 60: 540-545.PubMed
21.
Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH, Cantor H: T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci USA. 2005, 102: 17101-17106. 10.1073/pnas.0508666102.PubMedCentralCrossRefPubMed
22.
Kawamura K, Iyonaga K, Ichiyasu H, Nagano J, Suga M, Sasaki Y: Differentiation, maturation, and survival of dendritic cells by osteopontin regulation. Clin Diagn Lab Immunol. 2005, 12: 206-212.PubMedCentralPubMed
23.
Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000, 287: 860-864. 10.1126/science.287.5454.860.CrossRefPubMed
24.
Nau GJ, Liaw L, Chupp GL, Berman JS, Hogan BL, Young RA: Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun. 1999, 67: 4223-4230.PubMedCentralPubMed
25.
Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER: Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol. 2011, 92: 13-9.CrossRefPubMed
26.
Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF, Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011, 9: 280-293. 10.1158/1541-7786.MCR-10-0463.CrossRefPubMed
27.
Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS: Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol. 2010, 5: 1516-1523. 10.1097/JTO.0b013e3181eba6bd.PubMedCentralCrossRefPubMed
28.
Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, You Y: Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol. 2010, 12: 765-775. 10.1093/neuonc/noq006.PubMedCentralCrossRefPubMed
29.
Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW: Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 2009, 35: 1409-1416.PubMed
30.
Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB: Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA. 2010, 107: 3012-3017. 10.1073/pnas.0914902107.PubMedCentralCrossRefPubMed
31.
de Kleijn DP, Moll FL, Hellings WE, Ozsarlak-Sozer G, de Bruin P, Doevendans PA, Vink A, Catanzariti LM, Schoneveld AH, Algra A, Daemen MJ, Biessen EA, de Jager W, Zhang H, de Vries JP, Falk E, Lim SK, van der Spek PJ, Sze SK, Pasterkamp G: Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol. 2010, 30: 612-619. 10.1161/ATVBAHA.109.194944.CrossRefPubMed
32.
Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim HM, Kitamura Y, Yutani C, Nomura S: Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol. 1993, 143: 1003-1008.PubMedCentralPubMed
33.
Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C, Kon S, Denhardt D, Kitabatake A, Uede T: Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003, 23: 1029-1034. 10.1161/01.ATV.0000074878.29805.D0.CrossRefPubMed
34.
Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003, 112: 1318-1331.PubMedCentralCrossRefPubMed
35.
Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S: Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol. 2002, 72: 752-761.PubMed
36.
Baker-LePain JC, Nakamura MC, Shepherd J, von Scheven E: Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford). 2011, 50: 611-619. 10.1093/rheumatology/keq307.CrossRef
37.
Atamas SP, White B: Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev. 2003, 14: 537-550. 10.1016/S1359-6101(03)00060-1.CrossRefPubMed
38.
Kim JS, Bashir MM, Werth VP: Gottron's Papules Exhibit Dermal Accumulation of CD44 Variant 7 (CD44v7) and Its Binding Partner Osteopontin: A Unique Molecular Signature. J Invest Dermatol. 2012, 132: 1825-1832. 10.1038/jid.2012.54.PubMedCentralCrossRefPubMed
39.
Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME: Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA. 2008, 105: 7240-7245. 10.1073/pnas.0802465105.PubMedCentralCrossRefPubMed
40.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed
41.
McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH: Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 2428-2437. 10.1002/art.24677.PubMedCentralCrossRefPubMed
42.
Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY, Hwee Siew Howe, Tan Tock Seng Hospital Lupus Study Group, Mok MY, Harley JB, Guthridge JM, Song YW, Cho SK, Bae SC, Grossman JM, Hahn BH, Arnett FC, Shen N, Tsao BP: Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum. 2011, 63: 749-754. 10.1002/art.30193.PubMedCentralCrossRefPubMed
43.
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M, International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004, 65: 521-530. 10.1111/j.1523-1755.2004.00443.x.CrossRefPubMed
44.
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8: 492-502. 10.1038/sj.gene.6364408.PubMedCentralCrossRefPubMed
45.
Hua J, Kirou K, Lee C, Crow MK: Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006, 54: 1906-1916. 10.1002/art.21890.CrossRefPubMed
46.
Ibanez D, Urowitz MB, Gladman DD: Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol. 2003, 30: 1977-1982.PubMed
47.
R Development Core Team: R: A Language and Environment for Statistical Computing. 2009, Vienna, Austria: R Foundation for Statistical Computing
48.
Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD: Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007, 56: 622-630. 10.1002/art.22375.CrossRefPubMed
49.
Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54: 2951-2962. 10.1002/art.22044.CrossRefPubMed
50.
Ibanez D, Gladman DD, Urowitz MB: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol. 2005, 32: 824-827.PubMed
51.
Lacks S, White P: Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol. 1990, 17: 941-945.PubMed
52.
Tucker LB, Menon S, Schaller JG, Isenberg DA: Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995, 34: 866-872. 10.1093/rheumatology/34.9.866.CrossRefPubMed
53.
Brunner HI, Sherrard TM, Klein-Gitelman MS: Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2006, 55: 184-188. 10.1002/art.21845.CrossRefPubMed
54.
Brunner HI, Mina R, Pilkington C, Beresford MW, Reiff A, Levy DM, Tucker LB, Eberhard BA, Ravelli A, Schanberg LE, Saad-Magalhaes C, Higgins GC, Onel K, Singer NG, von Scheven E, Itert L, Klein-Gitelman MS, Punaro M, Ying J, Giannini EH: Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 2011, 63: 1213-1223. 10.1002/acr.20507.CrossRef
55.
Marhaug G, Shah V, Shroff R, Varsani H, Wedderburn LR, Pilkington CA, Brogan PA: Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008, 47: 1031-1037. 10.1093/rheumatology/ken136.CrossRef
56.
Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003, 170: 333-337. 10.1016/S0021-9150(03)00298-3.CrossRefPubMed
57.
Kurokawa M, Konno S, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M, Watanabe S, Homma T, Sato M, Takeuchi H, Hirose T, Huang SK, Adachi M: Effects of corticosteroids on osteopontin expression in a murine model of allergic asthma. Int Arch Allergy Immunol. 2009, 149 (Suppl 1): 7-13.PubMedCentralCrossRefPubMed
58.
Muscat JE, Wynder EL: Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. Cancer. 1992, 69: 2244-2251. 10.1002/1097-0142(19920501)69:9<2244::AID-CNCR2820690906>3.0.CO;2-O.CrossRefPubMed
59.
Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M, Hirokawa K, Okada S, Hatano M, Tokuhisa T, Uede T: Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest. 1998, 78: 1523-1533.PubMed
60.
Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, Bruemmer D: Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res. 2005, 96: e59-e67. 10.1161/01.RES.0000163630.86796.17.CrossRefPubMed
61.
Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998, 152: 353-358.PubMedCentralPubMed
62.
Nystrom T, Duner P, Hultgardh-Nilsson A: A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res. 2007, 313: 1149-1160. 10.1016/j.yexcr.2006.12.026.CrossRefPubMed
63.
Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T: CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999, 59: 219-226.PubMed
64.
Mori R, Shaw TJ, Martin P: Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008, 205: 43-51. 10.1084/jem.20071412.PubMedCentralCrossRefPubMed
65.
Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, Johnson RJ: Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999, 56: 571-580. 10.1046/j.1523-1755.1999.00580.x.CrossRefPubMed
Metadata
Title
Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus
Authors
Ornella J Rullo
Jennifer MP Woo
Miriam F Parsa
Alice DC Hoftman
Paul Maranian
David A Elashoff
Timothy B Niewold
Jennifer M Grossman
Bevra H Hahn
Maureen McMahon
Deborah K McCurdy
Betty P Tsao
Publication date
01-02-2013
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2013
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4150

Other articles of this Issue 1/2013

Arthritis Research & Therapy 1/2013 Go to the issue

Research article

CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice

Research article

Gene expression profiling of early intervertebral disc degeneration reveals a down-regulation of canonical Wnt signaling and caveolin-1 expression: implications for development of regenerative strategies

Research article

Periodic knee injections of collagen tripeptide delay cartilage degeneration in rabbit experimental osteoarthritis

Review

MicroRNA control in the development of systemic autoimmunity

Research article

Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study

Editorial

(Auto)immunity to cartilage matrix proteins - a time bomb?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits